Alphyn Biologics
Cincinnati
About Alphyn Biologics
Alphyn Biologics develops and advances therapeutic drug candidates focused on treating skin diseases using its proprietary multi-target Zabalafin Platform, aiming to address key biological drivers of conditions such as atopic dermatitis. Its lead candidate, Zabalafin Hydrogel, is a topical formulation in clinical trials that is designed to interact with immune-mediated inflammation, itch, and bacterial components of the disease simultaneously as part of a singular treatment approach. The company supports its pipeline of dermatologic therapeutics with multiple bioactive compounds intended to engage several mechanisms of action within skin disease pathology. Alphyn maintains an intellectual property portfolio that spans its platform and product candidates. Zabalafin Hydrogel has progressed through Phase 2 clinical evaluation with ongoing Phase 2b studies and associated research publications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $36.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: alphynbiologics.com
- Phone: +(443) 994-0101
Industries & Categories
Health Care, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alphyn-biologics-47562 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.